The evolving role of targeted drugs in the treatment of Hodgkin lymphoma

References

• Eichenauer DA, Engert A, Andre M, et al. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2014 Sep;25(Suppl 3):iii70–5. PubMed PMID: 25185243; eng. DOI:10.1093/annonc/mdu181
   PubMed Web of Science ®Google Scholar
• Wongso D, Fuchs M, Plutschow A, et al. Treatment-related mortality in patients with advanced-stage Hodgkin lymphoma: an analysis of the German Hodgkin Study Group. J Clin Oncol. 2013 Aug 01;31(22): 2819–2824. PubMed PMID: 23796987; eng. DOI:10.1200/JCO.2012.47.9774
   PubMed Web of Science ®Google Scholar
• Schaapveld M, Aleman BM, Van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med. 2015 Dec 24;373(26): 2499–2511. PubMed PMID: 26699166; eng. DOI:10.1056/NEJMoa1505949
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Thielen I, Haverkamp H, et al. Therapy-related acute myeloid leukemia and myelodysplastic syndromes in patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood. 2014 Mar 13;123(11): 1658–1664. PubMed PMID: 24478403; eng. DOI:10.1182/blood-2013-07-512657
   PubMed Web of Science ®Google Scholar
• Behringer K, Mueller H, Goergen H, et al. Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study Group HD13 to HD15 trials. J Clin Oncol. 2013 Jan 10;31(2): 231–239. PubMed PMID: 23150709; eng. DOI:10.1200/JCO.2012.44.3721
   PubMed Web of Science ®Google Scholar
• Van Nimwegen FA, Ntentas G, Darby SC, et al. Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood. 2017 Jan 31. PubMed PMID: 28143884; eng. DOI:10.1182/blood-2016-09-740332
   Web of Science ®Google Scholar
• Boll B, Goergen H, Behringer K, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016 May 05;127(18): 2189–2192. PubMed PMID: 26834240; eng. DOI:10.1182/blood-2015-11-681064
   PubMed Web of Science ®Google Scholar
• Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma. J Natl Compr Canc Netw. 2011 Sep 01;9(9):1020–1058. PubMed PMID: 21917626; eng.
   PubMed Web of Science ®Google Scholar
• Josting A, Muller H, Borchmann P, et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin’s lymphoma. J Clin Oncol. 2010 Dec 01;28(34): 5074–5080. PubMed PMID: 20975066; eng. DOI:10.1200/JCO.2010.30.5771
   PubMed Web of Science ®Google Scholar
• Arai S, Fanale M, DeVos S, et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant.Leuk Lymphoma. 2013 Nov;54(11):2531–2533. PubMed PMID: 23617324; eng. DOI:10.3109/10428194.2013.798868
   PubMed Web of Science ®Google Scholar
• Martinez C, Canals C, Sarina B, et al. Identification of prognostic factors predicting outcome in Hodgkin’s lymphoma patients relapsing after autologous stem cell transplantation.Ann Oncol. 2013 Sep;24(9):2430–2434. PubMed PMID: 23712545; eng. DOI:10.1093/annonc/mdt206
   PubMed Web of Science ®Google Scholar
• Von Tresckow B, Muller H, Eichenauer DA, et al. Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant.Leuk Lymphoma. 2014 Aug;55(8):1922–1924. PubMed PMID: 24138304; eng. DOI:10.3109/10428194.2013.854888
   PubMed Web of Science ®Google Scholar
• Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010 Nov 04;363(19): 1812–1821. PubMed PMID: 21047225; eng. DOI:10.1056/NEJMoa1002965
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015 Jan 22;372(4): 311–319. PubMed PMID: 25482239; PubMed Central PMCID: PMC4348009. eng. DOI:10.1056/NEJMoa1411087
   PubMed Web of Science ®Google Scholar
• Armand P, Shipp MA, Ribrag V, et al. Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016 Jun 27. PubMed PMID: 27354476; eng. DOI:10.1200/JCO.2016.67.3467
   PubMed Web of Science ®Google Scholar
• Horie R, Watanabe T CD30: expression and function in health and disease. Semin Immunol. 1998 Dec;10(6):457–470. PubMed PMID: 9826579; eng. DOI:10.1006/smim.1998.0156
   PubMed Web of Science ®Google Scholar
• Ansell SM, Horwitz SM, Engert A, et al. Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin’s lymphoma and anaplastic large-cell lymphoma. J Clin Oncol. 2007 Jul 01;25(19): 2764–2769. PubMed PMID: 17515574; eng. DOI:10.1200/JCO.2006.07.8972
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Leonard JP, Younes A, et al. A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma.Br J Haematol. 2009 Jul;146(2):171–179. PubMed PMID: 19466965; eng. DOI:10.1111/j.1365-2141.2009.07740.x
   PubMed Web of Science ®Google Scholar
• Rothe A, Sasse S, Topp MS, et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015 Jun 25;125(26): 4024–4031. PubMed PMID: 25887777; PubMed Central PMCID: PMC4528081. eng. DOI:10.1182/blood-2014-12-614636
   PubMed Web of Science ®Google Scholar
• Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003 Aug 15;102(4): 1458–1465. PubMed PMID: 12714494; eng. DOI:10.1182/blood-2003-01-0039
   PubMed Web of Science ®Google Scholar
• Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012 Jun 20;30(18):2183–2189. PubMed PMID: 22454421; PubMed Central PMCID: PMC3646316. eng. DOI:10.1200/JCO.2011.38.0410
   PubMed Web of Science ®Google Scholar
• Gopal AK, Chen R, Smith SE, et al. Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood. 2015 Feb 19;125(8): 1236–1243. PubMed PMID: 25533035; PubMed Central PMCID: PMC4335079. eng. DOI:10.1182/blood-2014-08-595801
   PubMed Web of Science ®Google Scholar
• Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016 Sep 22;128(12): 1562–1566. PubMed PMID: 27432875; eng. DOI:10.1182/blood-2016-02-699850
   PubMed Web of Science ®Google Scholar
• Moskowitz AJ, Schoder H, Yahalom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin’s lymphoma: a non-randomised, open-label, single-centre, phase 2 study.Lancet Oncol. 2015 Mar;16(3):284–292. PubMed PMID: 25683846; eng. DOI:10.1016/S1470-2045(15)70013-6
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015 May 09;385(9980):1853–1862. PubMed PMID: 25796459; eng. DOI:10.1016/S0140-6736(15)60165-9
   PubMed Web of Science ®Google Scholar
• LaCasce AS, Bociek G, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active salvage treatment regimen for patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;126(23):3982–3982.
   Web of Science ®Google Scholar
• Cassaday RD, Fromm J, Cowan AJ, et al. Safety and activity of Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): initial results of a phase I/II trial. Blood. 2016;128(22):1834–1834.
   PubMed Web of Science ®Google Scholar
• Kumar A, Casulo C, Yahalom J, et al. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood. 2016 Sep 15;128(11): 1458–1464. PubMed PMID: 27458003; eng. DOI:10.1182/blood-2016-03-703470
   PubMed Web of Science ®Google Scholar
• Younes A, Connors JM, Park SI, et al. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: a phase 1, open-label, dose-escalation study. Lancet Oncol. 2013 Dec;14(13):1348–1356. PubMed PMID: 24239220; eng. DOI:10.1016/S1470-2045(13)70501-1.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Eichenauer DA, Pluetschow A, et al. Targeted beacopp variants in patients with newly diagnosed advanced stage classical Hodgkin lymphoma: final analysis of a randomized phase II study. Blood. 2015;126(23):580–580.
   Web of Science ®Google Scholar
• Forero-Torres A, Holkova B, Goldschmidt J, et al. Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood. 2015 Dec 24;126(26): 2798–2804. PubMed PMID: 26377597; PubMed Central PMCID: PMC4692140. eng. DOI:10.1182/blood-2015-06-644336
   PubMed Web of Science ®Google Scholar
• Roemer MG, Advani RH, Ligon AH, et al. PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome. J Clin Oncol. 2016 Aug 10;34(23): 2690–2697. PubMed PMID: 27069084; PubMed Central PMCID: PMC5019753. eng. DOI:10.1200/JCO.2016.66.4482
   PubMed Web of Science ®Google Scholar
• Brockelmann PJ, Borchmann P, Engert A Current and future immunotherapeutic approaches in Hodgkin lymphoma. Leuk Lymphoma. 2016 Sep;57(9):2014–2024. PubMed PMID: 27243940; eng. DOI:10.1080/10428194.2016.1185789
   PubMed Web of Science ®Google Scholar
• Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016 Sep;17(9):1283–1294. PubMed PMID: 27451390; eng. DOI:10.1016/S1470-2045(16)30167-X.
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Engert A, Younes A, et al. Checkmate 205 update with minimum 12-month follow up: a phase 2 study of nivolumab in patients with relapsed/refractory classical Hodgkin lymphoma. Blood. 2016;128(22):1110–1110.
   Web of Science ®Google Scholar
• Armand P, Shipp MA, Ribrag V, et al. Pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: long-term efficacy from the phase 1b keynote-013 study. Blood. 2016;128(22):1108–1108.
   Web of Science ®Google Scholar
• Chen R, Zinzani PL, Fanale MA, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017 Apr 25; JCO2016721316. PubMed PMID: 28441111; eng. DOI:10.1200/JCO.2016.72.1316
   Web of Science ®Google Scholar
• Eichenauer DA, Fuchs M, Pluetschow A, et al. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. Blood. 2011 Oct 20;118(16): 4363–4365. PubMed PMID: 21828141; eng. DOI:10.1182/blood-2011-06-361055
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Plutschow A, Fuchs M, et al. Long-term course of patients with stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. J Clin Oncol. 2015 Sep 10;33(26): 2857–2862. PubMed PMID: 26240235; eng. DOI:10.1200/JCO.2014.60.4363
   PubMed Web of Science ®Google Scholar
• Advani RH, Horning SJ, Hoppe RT, et al. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. J Clin Oncol. 2014 Mar 20;32(9): 912–918. PubMed PMID: 24516013; eng. DOI:10.1200/JCO.2013.53.2069
   PubMed Web of Science ®Google Scholar
• Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008 Jan 01;111(1): 109–111. PubMed PMID: 17938252; eng. DOI:10.1182/blood-2007-03-078725
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Goergen H, Plutschow A, et al. Ofatumumab in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: results of a phase II study from the German Hodgkin Study Group.Leukemia. 2016 Jun;30(6):1425–1427. PubMed PMID: 26585412; eng. DOI:10.1038/leu.2015.321
   PubMed Web of Science ®Google Scholar
• Younes A, Oki Y, McLaughlin P, et al. Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood. 2012 May 03;119(18): 4123–4128. PubMed PMID: 22371887; PubMed Central PMCID: PMC3359733. eng. DOI:10.1182/blood-2012-01-405456
   PubMed Web of Science ®Google Scholar
• Kasamon YL, Jacene HA, Gocke CD, et al. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood. 2012 May 03;119(18): 4129–4132. PubMed PMID: 22343727; PubMed Central PMCID: PMC3359734. eng. DOI:10.1182/blood-2012-01-402792
   PubMed Web of Science ®Google Scholar
• Borchmann P, Haverkamp H, Lohri A, et al. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin’s lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group. Lancet Oncol. 2017 Feb 21. PubMed PMID: 28236583; eng. DOI:10.1016/S1470-2045(17)30103-1
   Web of Science ®Google Scholar
• Martinez C, Diaz-Lopez A, Rodriguez-Calvillo M, et al. Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy.Br J Haematol. 2016 Sep;174(6):859–867. PubMed PMID: 27185197; eng. DOI:10.1111/bjh.14133
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Larson S, Trinkaus K, et al. A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood. 2011 Nov 10;118(19): 5119–5125. PubMed PMID: 21937701; PubMed Central PMCID: PMC3217400. eng. DOI:10.1182/blood-2011-07-362475
   PubMed Web of Science ®Google Scholar
• Böll B, Plütschow A, Fuchs M, et al. German Hodgkin Study Group phase I trial of doxorubicin, vinblastine, dacarbazine, and lenalidomide (AVD-Rev) for older Hodgkin lymphoma patients. Blood. 2013;122(21):3054–3054.
   PubMed Web of Science ®Google Scholar
• Johnston PB, Inwards DJ, Colgan JP, et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma.Am J Hematol. 2010 May;85(5):320–324. PubMed PMID: 20229590; PubMed Central PMCID: PMC4420736. eng. DOI:10.1002/ajh.21664
   PubMed Web of Science ®Google Scholar
• Von Tresckow B, Pluetschow A, Haverkamp H, et al. A phase I study of everolimus in combination with time-intensified DHAP (Dexamethasone, High-Dose AraC [Cytarabine], Cisplatinum) in patients with relapsed or refractory Classical Hodgkin Lymphoma (cHL). Blood. 2014;124(21):4433–4433.
   Web of Science ®Google Scholar
• Younes A, Oki Y, Bociek RG, et al. Mocetinostat for relapsed classical Hodgkin’s lymphoma: an open-label, single-arm, phase 2 trial.Lancet Oncol. 2011 Dec;12(13):1222–1228. PubMed PMID: 22033282; PubMed Central PMCID: PMC5042214. eng. DOI:10.1016/S1470-2045(11)70265-0
   PubMed Web of Science ®Google Scholar
• Younes A, Sureda A, Ben-Yehuda D, et al. Panobinostat in patients with relapsed/refractory Hodgkin’s lymphoma after autologous stem-cell transplantation: results of a phase II study. J Clin Oncol. 2012 Jun 20;30(18): 2197–2203. 1350.PubMed PMID: 22547596; eng. DOI:10.1200/JCO.2011.38
   PubMed Web of Science ®Google Scholar
• Von Tresckow B, Morschhauser F, Szer J, et al. Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation.Leuk Lymphoma. 2017 Jan;58(1):222–225. PubMed PMID: 27184350; eng. DOI:10.1080/10428194.2016.1182164
   PubMed Web of Science ®Google Scholar
• Carson KR, Newsome SD, Kim EJ, et al. Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project. Cancer. 2014 Aug 15;120(16): 2464–2471. PubMed PMID: 24771533; PubMed Central PMCID: PMC4460831. eng. DOI:10.1002/cncr.28712
   PubMed Web of Science ®Google Scholar
• Gandhi MD, Evens AM, Fenske TS, et al. Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event. Blood. 2014 May 01;123(18): 2895–2897. PubMed PMID: 24786458; PubMed Central PMCID: PMC4007615. eng. DOI:10.1182/blood-2014-03-561878
   PubMed Web of Science ®Google Scholar
• Villadolid J, Amin A Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015 Oct;4(5):560–575. PubMed PMID: 26629425; PubMed Central PMCID: PMC4630514. eng. DOI:10.3978/j.issn.2218-6751.2015.06.06
   PubMed Web of Science ®Google Scholar
• Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016 Nov 03;375(18): 1749–1755. PubMed PMID: 27806233; PubMed Central PMCID: PMC5247797. eng. DOI:10.1056/NEJMoa1609214
   PubMed Web of Science ®Google Scholar
• Herbaux C, Gauthier J, Brice P, et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood. 2017 May 04;129(18): 2471–2478. PubMed PMID: 28270452; eng. DOI:10.1182/blood-2016-11-749556
   PubMed Web of Science ®Google Scholar
• Haverkos BM, Abbott D, Hamadani M, et al. PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017 May 03. PubMed PMID: 28468799; eng. DOI:10.1182/blood-2017-01-761346
   PubMed Web of Science ®Google Scholar
• Chen R, Palmer JM, Thomas SH, et al. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012 Jun 28;119(26): 6379–6381. PubMed PMID: 22611160; PubMed Central PMCID: PMC3383201. eng. DOI:10.1182/blood-2012-03-418673
   PubMed Web of Science ®Google Scholar
• Merryman RW, Kim HT, Zinzani PL, et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood. 2017 Mar 09;129(10): 1380–1388. PubMed PMID: 28073785; PubMed Central PMCID: PMC5345733. eng. DOI:10.1182/blood-2016-09-738385
   PubMed Web of Science ®Google Scholar